Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy (surgery) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy.i The approval of this perioperative (before and after surgery) treatment was based on results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905), which were presented during a Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2025.
Texas sues Sanofi and Bristol-Myers Squibb over alleged Plavix failures, as Paxton also finalizes a $41.5 million settlement with Pfizer and Tris over quality issues in children's medication.
Artificial intelligence is rapidly transforming America's healthcare system, offering immediate and profound benefits across the entire spectrum of care, from individual patients to providers and public health initiatives. For patients, AI is leading to earlier, more accurate diagnoses and highly personalized treatment plans. Machine learning algorithms can analyze vast amounts of medical data, including imaging [...]
Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Although Cincinnati Financial has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (JV) entity GMP Bio, driven by a new independent valuation https://nnw.fm/5K7hg indicating a potential step-up in asset value. This key shift strengthens Oncotelic Therapeutics position in the oncology space as the company works to make a difference, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)
Zoetis’s stock price has taken a beating over the past six months, shedding 28.6% of its value and falling to a new 52-week low of $116.88 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
As November 2025 unfolds, the financial markets find themselves in a delicate balance, with gold demonstrating remarkable resilience and even significant appreciation, while global stock markets grapple with persistent jitters. This dynamic environment is further complicated by a deeply divided Federal Reserve, whose uncertain path on interest rate cuts continues
Washington D.C. – November 19, 2025 – The U.S. Labor Department announced today that it would not release a full jobs report for October due to a prolonged federal government shutdown that recently concluded. This unprecedented decision leaves a critical void in economic data, plunging policymakers, economists, and financial markets
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of mixed topline results from its pivotal RISE UP Phase 3 trial for mitapivat in sickle cell disease (SCD). While the investigational therapy
Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025 earnings report. The biopharmaceutical company not only significantly surpassed revenue forecasts but also celebrated the highly successful commercial launch of
Global financial markets are currently gripped by a palpable sense of unease and heightened volatility as investors brace for a barrage of crucial economic and corporate reports in the coming weeks. A complex interplay of economic uncertainties, evolving monetary policies, and persistent geopolitical tensions has created a challenging landscape, prompting
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
As November 2025 unfolds, the global financial landscape remains under the persistent shadow of elevated inflation and a complex, albeit moderating, interest rate environment. This intricate economic backdrop is casting a pall over global markets, leading to pronounced investor volatility and significantly impacting commodity prices. While some regions show signs
